Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Future Oncology

Volumn 3, Issue 3, 2007, Pages 255-262

  Smith, Stepen ^a   Sweetenham, John W ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bexxar ; I131; Indolent NHL; Radioimmunoconjugate; Tositumomab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GROWTH FACTOR; MELPHALAN; POTASSIUM IODIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; HYPOTHYROIDISM; INFECTION; LEUKEMIA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIATION PROTECTION; RADIOSENSITIVITY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 34347371248     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.255     Document Type: Article

References (26)

1. McLaughlin P, Grillo-Lopez AJ, Link BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Cin. Oncol. 16(8), 2825-2833 (1998).
2. Coiffier B, Lepage E, Briere J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
3. Feugier P, Van Hoof A, Sebban C et al.: Long-term results of the R-CHOP study in die treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe D'etudes des lymphomes de l'Adulte. J. Clin. Oncol. 23(18), 4117-4126 (2005).
4. Hiddemann W, Kneba M, Dreyling M et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the german low-grade lymphoma study group. Blood 106(12), 3725-3732 (2005).
5. Schulz H, Skoetz N, Bohlius J et al.: Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood (ASH Annual Meeting Abstracts). 106(11), 351 (2005).
6. Cheson BD: Radioimmunotherapy of non-hodgkin's lymphomas. Curr. Drug Targets 7(10), 1293-1300 (2006).
7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS: Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001. Blood 107(1), 265-276 (2006).
8. Smith MR: Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22(47), 7359-7368 (2003).
9. Kaminski MS, Zasadny KR, Francis IR et al.: Radioimmunotherapy of B-cell lymphoma with [13I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7), 459-465 (1993).
10. Wahl RL: The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin. Oncol. 30(2 Suppl. 4), 31-38 (2003).
11. Kaminski MS, Estes J, Zasadny KR et al.: Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-hodgkin lymphoma: Updated results and long-term follow-up of the university of michigan experience. Blood 96(4), 1259-1266 (2000).
12. Vose JM, Wahl RL, Saleh M et al.: Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-hodgkin's lymphomas. J. Clin. Oncol. 18(6), 1316-1323 (2000).
13. Kaminski MS, Zelenetz AD, Press OW et al.: Pivotal study of iodine I 131 tositumomab fbr chemotherapy-refractory low-grade or transformed low-grade B-cell non-hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
14. Davies AJ, Rohatiner AZ, Howell S et al.: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-hodgkin's lymphoma. J. Clin. Oncol. 22(8), 1469-1479 (2004).
15. Horning SJ, Younes A, Jain V et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 23(4), 712-719 (2005).
16. Fisher RI, Kaminski MS, Wahl RL et al.: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-hodgkin's lymphomas. J. Clin. Oncol. 23(30), 7565-7573 (2005).
17. Kaminski MS, Tuck M, Estes J et al.: 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352(5), 441-449 (2005).
18. Press OW, Unger JM, Braziel RM et al.: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-hodgkin's lymphoma: five-year follow-up of southwest oncology group protocol S9911. J. Clin. Oncol. 24(25), 4143-4149 (2006).
19. Leonard JP, Coleman M, Kostakoglu L et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol. 23(24), 5696-5704 (2005).
20. Press OW, Eary JF, Gooley T et al.: A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96(9), 2934-2942 (2000).
21. Vose JM, Bierman PJ, Enke C et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-hodgkin's lymphoma. J. Clin. Oncol. 23 (3), 461-467 (2005).
22. Gopal AK, Gooley TA, Maloney DG et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-hodgkin lymphoma: A multivariable cohort analysis. Blood 102(7), 2351-2357 (2003).
23. Gopal AY, Rajendran JG, Petersdorf SH et al.: High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood99(9), 3158-3162 (2002).
24. Bennett JM, Kaminski MS, Leonard JP et al.: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105(12), 4576-4582 (2005).
25. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S: Treatment-related myelodysplasia and acute leukemia in non-hodgkin's lymphoma patients. J. Clin. Oncol. 21(5), 897-906 (2003).
26. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-hodgkin's lymphoma: Long-term follow-up of no initial therapy. J. Clin. Oncol. 22(8), 1454-1459 (2004).